ZYBERNO
Stock Report
Updated Aug 31, 2026

Kestra Medical Technologies, Ltd. (KMTS)

Healthcare • NASDAQ

$25.64

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
Kestra Medical Technologies, Ltd. (KMTS) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.16x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-259.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Kestra Medical Technologies, Ltd. (KMTS) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:25.64
Market Cap:$1.43B

Valuation Multiples (2)

P/B Ratio:4.97x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$1.18B

Price Action & Momentum (3)

Momentum Percentile:83 / 100
% of 52-Week High:85.5%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-25.9%
Fundamental Growth Rate (g):67.2%

Margin Analysis (1)

Ebitda Margin:-132.5%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:7.32x
Quick Ratio:7.32x
Cash Ratio:6.79x

Leverage Analysis (3)

Debt To Equity Ttm:0.16x
Debt-to-Equity Ratio:0.16x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-71.37x
Times Interest Earned:-71.37

Capital Structure (4)

Working Capital:271,132,000.00
Cash And Cash Equivalents:291,321,000.00
Long Term Debt:$42.26M
Net Debt:-$249.05M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$95.13M
Cost Of Revenue Ttm:$46.26M

Profitability Breakdown (2)

$48.86M-$134.74M

Bottom Line Performance (3)

-$131.61M
Income Before Tax:-$34.13M
Ebitda Ttm:-126,032,000.00

Operating Expenses (5)

Operating Expenses:47,671,000.00
R And D Expense:4,972,000.00
Sga Expense:42,699,000.00
Income Tax Expense:$35.00K
Interest Expense:1,888,000.00

Expense Ratios (3)

R And D To Revenue Percentage:20.3%
Sga To Revenue Percentage:173.9%
Ebitda Margin:-132.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$379.34M
Current Assets:$314.06M
Ppe Net:53,799,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:91,353,000.00
Current Liabilities:42,931,000.00
Long Term Debt:$42.26M
Short Term Debt:$10.00K

Equity & Capital (3)

Equity:$287.99M
Retained Earnings:-$613.03M
Common Stock:58,349,000.00

Working Capital Items (3)

Accounts Receivable:12,709,000.00
Inventory:0.00
Accounts Payable:24,023,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:10,108,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$81.70M-$116.60M

Investment Activities (1)

Investing Cash Flow:-$8.23M

Financing Activities (3)

Financing Cash Flow:-$1.88M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:149,291,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:8,709,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$2.36

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.70
Operating Cash Flow Per Share:-$1.46

Book Value & Capital (2)

Book Value Per Share:$5.16
Cash Per Share:5.22

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.32x
Working Capital Turnover Ttm:0.35x

Receivables Management (2)

Receivables Turnover Ttm:7.48x
Days Sales Outstanding Ttm:48.76

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:189.53
Cash Conversion Cycle:-1,139.77
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-25.9%
Fundamental Growth Rate (g):67.2%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:KMTS
Company Name:Kestra Medical Technologies, Ltd.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:55.85M
Shares Outstanding Basic:55.85M
Shares Outstanding Diluted:55.85M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 23:54:27 UTC
Data Timestamp:2026-08-31T23:54:27.316457
Scroll to Top